The tumor delivery of nab-paclitaxel has been thought to be an active process, through which the nanoparticles can bind gp60 expressed on the tumor vascular endothelium facilitating caveolin-1-mediated transcytosis [22,23]. Here, CAV1 is linked to neoplasm.